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The α-2 agonists as adjuncts to improve sedation, 
analgesia, and euphoria in anesthesia practice and partial 
block of acute withdrawal symptoms in chronic opioid 
users have been used for decades (1). α-2 agonists can 
produce sedation, analgesia, and euphoric effects 
centrally through locus ceruleus while it is postulated that 
the spinal mechanism is the main route for creating 
analgesic effects of α-2 agonists (2). Dexmedetomidine is 
around 8 times more selective in its alpha 2 
adrenoreceptor affinity than clonidine (alpha 2: 
alpha1affinity in clonidine is 220: 1 while in 
dexmedetomidine it is 1620:1) and hence it can be used 
in higher doses with less α1 effect. Dexmedetomidine has 
more intense motor block ability and higher quality of 
sedation without adding the noticeable side effects (2,3).  
There are a lot of comparative studies, including 
both clinical and cellular studies added with many 
systematic reviews about the effects of dexmedetomidine 
and clonidine as adjuvants to local anesthetics for 
improving the quality of the motor and sensory nerve 
blocks or as adjuvants for facilitating the quality of 
sedation and analgesia during general anesthesia or in 
intensive care unit patients. Moreover, the hemodynamic 
effects of these two medications and their effects on 
postoperative complications have been assessed in 
different studies; the more reasonable properties of 
dexmedetomidine during local/general anesthesia and 
providing a better quality of sedation with its fewer side 
effects at the cellular level in different studies are 
noticeable (4,5). The neuroprotective effects of 
dexmedetomidine have created new cellular and 
molecular windows to a challenging field with limited 
available solutions; discussed in this issue by 
Hajiesmaeili et al. (6). 
Since the arrival of alpha 2 agonists in the field of 
anesthesia, their subgroup medications and the manner of 
applications have been noticed by anesthesiologists and 
we can say that nowadays the alpha 2 agonists have 
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